The correlation between miR-200c and the severity of interstitial lung disease associated with different connective tissue diseases

Scandinavian Journal of Rheumatology

Volumn 46, Issue 2, 2017, Pages 122-129

  Jiang, Z ^a,b   Tao, J H ^a   Zuo, T ^a   Li, X M ^a   Wang, G S ^a   Fang, X ^a   Xu, X L ^a   Li, X P ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 200C; ANTINUCLEAR ANTIBODY; JO-1 ANTIBODY; MICRORNA; MIRN200 MICRORNA, HUMAN;

ADULT; ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE EXPRESSION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC SCLEROSIS; AGED; BLOOD; COMPLICATION; LUNG DISEASES, INTERSTITIAL; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; VITAL CAPACITY; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; CONNECTIVE TISSUE DISEASES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MICRORNAS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 84974830983     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2016.1167950     Document Type: Article

References (32)

1. Selva-O’Callaghan A, Labrador-Horrillo M, Muñoz-Gall X, Martínez-Gomez X, Majó-Masferrer J, Solans-Laque R, et al. Polymyositis/dermatomyositis-associated lung disease:analysis of a series of 81 patients. Lupus 2005;14:534–42.
2. Mimori T, Nakashima R, Hosono Y., Interstitial lung disease in myositis:clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep 2012;14:264–74.
3. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis:association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009;60:2193–200.
4. Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 2012;51:1563–70.
5. Váncsa A, Csípo I, Németh J, Dévényi K, Gergely L, Dankó K. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int 2009;29:989–94.
6. Kumánovics G, Minier T, Radics J, Pálinkás L, Berki T, Czirják L. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol 2008;26:414–20.
7. Yang S, Banerjee S, De Freitas A, Sanders YY, Ding Q, Matalon S, et al. Participation of miR-200 in pulmonary fibrosis. Am J Pathol 2012;180:484–93.
8. Austin JHM, Müller NL, Friedman PJ, Hansell DM, Naidich DP, Remy-Jardin M, et al. Glossary of terms for CT of the lungs:recommendations of the Nomenclature Committee of the Fleischner Society. Radiology 1996;200:327–31.
9. Hua-Huy T, Rivière S, Tiev KP, Dinh-Xuan AT. Use of pulmonary function tests and biomarkers studies to diagnose and follow-up interstitial lung disease in systemic sclerosis. Rev Pneumol Clin 2014;70:335–42.
10. Maldonado F, Patel RR, Iyer VN, Yi ES, Ryu JH. Are respiratory complications common causes of death in inflammatory myopathies? An autopsy study. Respirology 2012;17:455–60.
11. Selman M, King TE, Pardo A, American Thoracic Society, European Respiratory Society, American College of Chest Physicians. Idiopathic pulmonary fibrosis:prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136–51.
12. Wynn TA, Ramalingam TR. Mechanisms of fibrosis:therapeutic translation for fibrotic disease. Nat Med 2012;18:1028–40.
13. Lewis BP, Shih I-H, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115:787–98.
14. Robins H, Li Y, Padgett RW. Incorporating structure to predict microRNA targets. Proc Natl Acad Sci USA 2005;102:4006–9.
15. Bartel DP. MicroRNAs:target recognition and regulatory functions. Cell 2009;136:215–33.
16. Ha T-Y. MicroRNAs in human diseases:from autoimmune diseases to skin, psychiatric and neurodegenerative diseases. Immune Netw 2011;11:227–44.
17. Patel V, Noureddine L. MicroRNAs and fibrosis. Curr Opin Nephrol Hypertens 2012;21:410–16.
18. Margaritopoulos GA, Romagnoli M, Poletti V, Siafakas NM, Wells AU, Antoniou KM. Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis. Eur Respir Rev 2012;21:48–56.
19. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010;207:1589–97.
20. Tang J-M, He Q-Y, Guo R-X, Chang X-J. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006;51:181–91.
21. Conte E, Fruciano M, Fagone E, Gili E, Caraci F, Iemmolo M, et al. Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts:the role of class I P110 isoforms. PLoS One 2011;6:e24663.
22. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C, et al. MicroRNA expression in response to murine myocardial infarction:miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009;82:21–9.
23. Cushing L, Kuang PP, Qian J, Shao F, Wu J, Little F, et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol 2011;45:287–94.
24. Xiao J, Meng X-M, Huang XR, Chung AC, Feng Y-L, Hui DS, et al. miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol Ther 2012;20:1251–60.
25. Yang T, Liang Y, Lin Q, Liu J, Luo F, Li X, et al. miR-29 mediates TGFβ1-induced extracellular matrix synthesis through activation of PI3K-AKT pathway in human lung fibroblasts. J Cell Biochem 2013;114:1336–42.
26. Park S-Y, Lee JH, Ha M, Nam J-W, Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009;16:23–9.
27. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593–601.
28. Muangchan C, Harding S, Khimdas S, Bonner A, Canadian Scleroderma Research group, Baron M, et al. Association of C-reactive protein with high disease activity in systemic sclerosis:results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken) 2012;64:1405–14.
29. Liu X, Mayes MD, Pedroza C, Draeger HT, Gonzalez EB, Harper BE, et al. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res (Hoboken) 2013;65:1375–80.
30. Park JK, Gelber AC, George M, Danoff SK, Qubti MA, Christopher-Stine L. Pulmonary impairment, not muscle injury, is associated with elevated ESR in the idiopathic inflammatory myopathies. Rheumatology (Oxford) 2013;52:1336–8.
31. Mochizuki T, Aotsuka S, Satoh T. Clinical and laboratory features of lupus patients with complicating pulmonary disease. Respir Med 1999;93:95–101.
32. Yang G, Yang L, Wang W, Wang J, Wang J, Xu Z. Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression. Gene 2015;562:138–44.